Cargando…
Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane
Quetiapine Fumarate is potent, and the daily therapeutic dose can be delivered easily across the skin with the help of permeation enhancers. Quetiapine Fumarate-loaded transdermal patches were prepared by solvent evaporation technique. Various formulation parameters, excipients, and their combinatio...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143260/ https://www.ncbi.nlm.nih.gov/pubmed/35631867 http://dx.doi.org/10.3390/polym14101984 |
_version_ | 1784715761896390656 |
---|---|
author | Bhupathyraaj, Mullaicharam Vijaya Rani, K. Reeta Sridhar, Sathvik B. Shareef, Javed Thomas, Sabin Halligudi, Nirmala Sockalingam, Anbazhagan Mohandoss, Kiruba Sundar, Shyam |
author_facet | Bhupathyraaj, Mullaicharam Vijaya Rani, K. Reeta Sridhar, Sathvik B. Shareef, Javed Thomas, Sabin Halligudi, Nirmala Sockalingam, Anbazhagan Mohandoss, Kiruba Sundar, Shyam |
author_sort | Bhupathyraaj, Mullaicharam |
collection | PubMed |
description | Quetiapine Fumarate is potent, and the daily therapeutic dose can be delivered easily across the skin with the help of permeation enhancers. Quetiapine Fumarate-loaded transdermal patches were prepared by solvent evaporation technique. Various formulation parameters, excipients, and their combinations were optimized to get thin, translucent, smooth, stable, and high permeable character patches. A total number of 10 formulations were prepared. All formulations were subjected to various physicochemical evaluations. Three different formulations were prepared and F1, F2, and F3. Various physicochemical studies were carried out and found no significant difference between the three batches. The in vitro release study showed 74.29%, 82.73%, and 77.27%, respectively, up to 24 h. From the results, F2 has been selected as an optimized formulation and evaluated for skin irritation test. The results revealed that there is no irritation produced. The stability study results showed that there is no significant change from its initial nature till the period of three months in both temperatures. Quetiapine Fumarate Transdermal Patch F2 has achieved the goal of extended-release, cost-effectiveness, lowering the dose and frequency of drug administration, and thus may improve patient compliance. |
format | Online Article Text |
id | pubmed-9143260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91432602022-05-29 Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane Bhupathyraaj, Mullaicharam Vijaya Rani, K. Reeta Sridhar, Sathvik B. Shareef, Javed Thomas, Sabin Halligudi, Nirmala Sockalingam, Anbazhagan Mohandoss, Kiruba Sundar, Shyam Polymers (Basel) Article Quetiapine Fumarate is potent, and the daily therapeutic dose can be delivered easily across the skin with the help of permeation enhancers. Quetiapine Fumarate-loaded transdermal patches were prepared by solvent evaporation technique. Various formulation parameters, excipients, and their combinations were optimized to get thin, translucent, smooth, stable, and high permeable character patches. A total number of 10 formulations were prepared. All formulations were subjected to various physicochemical evaluations. Three different formulations were prepared and F1, F2, and F3. Various physicochemical studies were carried out and found no significant difference between the three batches. The in vitro release study showed 74.29%, 82.73%, and 77.27%, respectively, up to 24 h. From the results, F2 has been selected as an optimized formulation and evaluated for skin irritation test. The results revealed that there is no irritation produced. The stability study results showed that there is no significant change from its initial nature till the period of three months in both temperatures. Quetiapine Fumarate Transdermal Patch F2 has achieved the goal of extended-release, cost-effectiveness, lowering the dose and frequency of drug administration, and thus may improve patient compliance. MDPI 2022-05-13 /pmc/articles/PMC9143260/ /pubmed/35631867 http://dx.doi.org/10.3390/polym14101984 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bhupathyraaj, Mullaicharam Vijaya Rani, K. Reeta Sridhar, Sathvik B. Shareef, Javed Thomas, Sabin Halligudi, Nirmala Sockalingam, Anbazhagan Mohandoss, Kiruba Sundar, Shyam Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane |
title | Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane |
title_full | Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane |
title_fullStr | Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane |
title_full_unstemmed | Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane |
title_short | Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane |
title_sort | effect of polymers and permeation enhancers in the release of quetiapine fumarate transdermal patch through the dialysis membrane |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143260/ https://www.ncbi.nlm.nih.gov/pubmed/35631867 http://dx.doi.org/10.3390/polym14101984 |
work_keys_str_mv | AT bhupathyraajmullaicharam effectofpolymersandpermeationenhancersinthereleaseofquetiapinefumaratetransdermalpatchthroughthedialysismembrane AT vijayaranikreeta effectofpolymersandpermeationenhancersinthereleaseofquetiapinefumaratetransdermalpatchthroughthedialysismembrane AT sridharsathvikb effectofpolymersandpermeationenhancersinthereleaseofquetiapinefumaratetransdermalpatchthroughthedialysismembrane AT shareefjaved effectofpolymersandpermeationenhancersinthereleaseofquetiapinefumaratetransdermalpatchthroughthedialysismembrane AT thomassabin effectofpolymersandpermeationenhancersinthereleaseofquetiapinefumaratetransdermalpatchthroughthedialysismembrane AT halligudinirmala effectofpolymersandpermeationenhancersinthereleaseofquetiapinefumaratetransdermalpatchthroughthedialysismembrane AT sockalingamanbazhagan effectofpolymersandpermeationenhancersinthereleaseofquetiapinefumaratetransdermalpatchthroughthedialysismembrane AT mohandosskiruba effectofpolymersandpermeationenhancersinthereleaseofquetiapinefumaratetransdermalpatchthroughthedialysismembrane AT sundarshyam effectofpolymersandpermeationenhancersinthereleaseofquetiapinefumaratetransdermalpatchthroughthedialysismembrane |